Our Take
The piece identifies a real problem—early decisions in sterile injectable development carry outsized consequences—but offers no specifics on which decisions, what metrics to track, or how to measure success.
Why it matters
Biotech teams face compounded risk when lab protocols don't survive manufacturing scale-up; caught late, this can derail timelines and budgets. The clinic-readiness challenge is acute for small-molecule and biologic injectable programs.
Do this week
Development leads: audit your injectable formulation checklist against your manufacturing partner's constraints before IND submission, not after.
Early decisions in sterile injectables carry downstream weight
BioPharma Dive reports that sterile injectable development hinges on decisions made in the laboratory phase. The framing is straightforward: choices early in drug development shape the product's path through clinical trials and into manufacturing.
The article treats this as a planning problem, not a technical one. The core claim is that teams often defer critical questions until later stages, when design changes become costly and slow.
Manufacturing reality doesn't wait for clinical success
Injectable drugs face dual constraints: the formulation must work in the patient, and the process must scale to GMP standards. These are not sequential challenges. A drug that performs in preclinical work but cannot be manufactured reliably at clinical scale becomes an expensive failure.
The lag between lab optimization and manufacturing feedback is where most injectable programs find trouble. Teams that force alignment early—between chemistry, formulation science, and process engineering—reduce rework downstream. Teams that don't typically discover incompatibilities during Phase 2 scale-up, when design changes demand new stability data and manufacturing validation.
Map your formulation constraints before IND
Clinical development leaders should treat manufacturability as a gate, not a hope. This means: identify your contract manufacturer's process constraints (vial filling speed, sterilization method, stability chamber capacity) before finalizing your formulation. Validate that your lead candidate can survive those constraints without re-optimization. Document this alignment in your chemistry and manufacturing controls (CMC) section for the IND application.
The opportunity cost of delay is real. A formulation redesign post-IND can add 6 to 18 months to your development timeline and millions in unplanned costs. Early alignment costs less and moves faster.